Minerva Neurosciences, Inc. (NERV)
| Market Cap | 216.77M +1,280.7% |
| Revenue (ttm) | n/a |
| Net Income | -394.35M |
| EPS | -14.44 |
| Shares Out | 47.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,571 |
| Open | 4.420 |
| Previous Close | 4.420 |
| Day's Range | 4.345 - 4.560 |
| 52-Week Range | 1.930 - 12.460 |
| Beta | -0.11 |
| Analysts | Hold |
| Price Target | 10.33 (+127.53%) |
| Earnings Date | Aug 7, 2026 |
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NERV stock is "Hold." The 12-month stock price target is $10.33, which is an increase of 127.53% from the latest price.
News
Minerva upgraded to Buy from Hold at Jefferies
Jefferies upgraded Minerva (NERV) to Buy from Hold with a price target of $10, up from $7.50. The shares have sold despite the company’s execution, creating a favorable risk/reward ahead…
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to g...
Minerva Neurosciences Earnings release: Q2 2026
Minerva Neurosciences released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Minerva Neurosciences Quarterly report: Q2 2026
Minerva Neurosciences has published its Q2 2026 quarterly earnings report on August 7, 2026.
Minerva Neurosciences Transcript: Jefferies Global Healthcare Conference 2026
Roluperidone aims to address primary negative symptoms in schizophrenia through a paradigm-shifting monotherapy approach, with a robust phase III trial underway and key efficacy data expected in 2027. The program is supported by strong IP and ongoing FDA engagement.
Minerva Neurosciences Transcript: AGM 2026
Attendees approved all six proposals, including director elections, amendments to the certificate of incorporation, executive compensation, and auditor ratification. No questions were submitted, and voting results will be reported on Form 8-K.
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy Distinguished panel of experts in psychiatry and ne...
Minerva Neurosciences Slides: Corporate presentation
Minerva Neurosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–dr...
Minerva Neurosciences Earnings release: Q1 2026
Minerva Neurosciences released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Minerva Neurosciences Quarterly report: Q1 2026
Minerva Neurosciences has published its Q1 2026 quarterly earnings report on May 5, 2026.
Minerva Neurosciences Proxy statement: Proxy filing
Minerva Neurosciences filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Minerva Neurosciences Proxy statement: Proxy filing
Minerva Neurosciences filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Minerva initiated with an Outperform at Citizens
Citizens initiated coverage of Minerva (NERV) with an Outperform rating and $14 price target Minerva is developing roluperidone for the treatment of negative symptoms of schizophrenia, the analyst tel...
Minerva Neurosciences Proxy statement: Proxy filing
Minerva Neurosciences filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Minerva appoints Jim O’Connor as chief business officer
Minerva (NERV) announced a leadership transition with the appointment of Jim O’Connor as chief business officer, effective April 21, as Geoff Race, the company’s president, has elected to leave the…
Minerva Announces Leadership Transition
BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Minerva screens first patient in roluperidone trial
Minerva (NERV) announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of sc...
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2...
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data...
Minerva Neurosciences Transcript: Stifel 2026 Virtual CNS Forum
Negative symptoms in schizophrenia remain a major unmet need, with roluperidone showing promise as a monotherapy that improves both symptoms and functioning without typical antipsychotic side effects. The pivotal trial is underway, with top-line results expected in the second half of next year.
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Minerva price target raised to $7 from $4 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Minerva (NERV) to $7 from $4 and keeps a Neutral rating on the shares. The firm cites the “promising positioning” of the…
Minerva files $200M mixed securities shelf
09:23 EDT Minerva (NERV) files $200M mixed securities shelf